top of page

Chile deal opens wider American markets for Proteomics

Updated: Apr 17

Proteomics International Laboratories will now be able to sell its PromarkerD kidney disease test in Chile. Credit: File

Proteomics International Laboratories has signed a licence agreement to sell its PromarkerD predictive test for diabetic kidney disease (DKD) in Chile, expanding its reach into the lucrative Central and South American markets.

The deal with long-standing partner Omics Global Solutions will see the test made available in the Republic of Chile, which management says is home to 1.7 million adults living with diabetes – the equivalent of one in eight adults.

PromarkerD is a prognostic test that can predict future kidney function decline in patients with Type 2 diabetes, but who have no existing DKD. The company’s patented assessment uses a simple blood test to detect a unique “fingerprint” of the early onset of the disease by measuring three protein markers, combined with three routinely-available, conventional clinical variables that include age, high-density lipoprotein cholesterol and estimated glomerular filtration rate.

A cloud-based algorithm, the “PromarkerD Hub” integrates the results into a risk report, classifying patients as low, moderate or high risk.

Proteomics says clinical studies published in leading journals show PromarkerD correctly predicted up to 86 per cent of otherwise healthy diabetics, who went on to develop DKD up to four years before clinical symptoms appeared.

The licence with Omics is for five years, can be extended by mutual agreement and is exclusive to Chile. The test will initially be targeted at Chile’s private payer market, with Omics also targeting expansion into other markets in Central and South America.

The company was the first licence partner for PromarkerD (sold as Innovatio ND2), launching the test in Puerto Rico and the Dominican Republic ahead of entry to the United States market. We are delighted to be expanding the relationship with Omics to bring the test to patients in South America. Proteomics International Laboratories managing director Dr Richard Lipscombe.

Globally, there are 537 million adults living with diabetes – a daunting tally that is forecast to reach 783 million by 2045. In the US alone, an estimated 32 million people – or 11 per cent of the adult population – live with diabetes, costing that country a whopping US$130 billion (AU$198 billion) a year.

In Chile, the number of people with the condition has risen almost 50 per cent in the past decade.

Just last month, Proteomics received a $1.85 million tax rebate boost under the Australian Government’s research and development (R&D) incentive scheme for the 2023 fiscal year. The company says the significant rebate will help in its bid to commercialise PromarkerD and further develop blood tests for endometriosis and oesophageal cancer.

The deal with Omics not only provides Proteomics with a key market in Chile, it also opens the door to additional opportunities in the greater Central and South American region.

Is your ASX-listed company doing something interesting? Contact:


bottom of page